nodes	percent_of_prediction	percent_of_DWPC	metapath
Frovatriptan—Migraine—Niacin—atherosclerosis	0.00405	0.00517	CcSEcCtD
Frovatriptan—Affect lability—Pravastatin—atherosclerosis	0.00399	0.00509	CcSEcCtD
Frovatriptan—Muscular weakness—Simvastatin—atherosclerosis	0.00395	0.00505	CcSEcCtD
Frovatriptan—Rhinitis—Rosuvastatin—atherosclerosis	0.00392	0.00501	CcSEcCtD
Frovatriptan—Pharyngitis—Rosuvastatin—atherosclerosis	0.00388	0.00496	CcSEcCtD
Frovatriptan—Mood swings—Pravastatin—atherosclerosis	0.00384	0.0049	CcSEcCtD
Frovatriptan—Muscular weakness—Niacin—atherosclerosis	0.00363	0.00463	CcSEcCtD
Frovatriptan—Muscular weakness—Pravastatin—atherosclerosis	0.00357	0.00456	CcSEcCtD
Frovatriptan—Dysphagia—Niacin—atherosclerosis	0.00356	0.00454	CcSEcCtD
Frovatriptan—Arrhythmia—Rosuvastatin—atherosclerosis	0.00349	0.00446	CcSEcCtD
Frovatriptan—Sinusitis—Lovastatin—atherosclerosis	0.00346	0.00442	CcSEcCtD
Frovatriptan—Depression—Simvastatin—atherosclerosis	0.00344	0.0044	CcSEcCtD
Frovatriptan—Mental disorder—Rosuvastatin—atherosclerosis	0.00343	0.00437	CcSEcCtD
Frovatriptan—Sweating increased—Pravastatin—atherosclerosis	0.00341	0.00436	CcSEcCtD
Frovatriptan—Sinusitis—Ezetimibe—atherosclerosis	0.0034	0.00434	CcSEcCtD
Frovatriptan—Flatulence—Rosuvastatin—atherosclerosis	0.00336	0.00428	CcSEcCtD
Frovatriptan—Sinusitis—Simvastatin—atherosclerosis	0.00324	0.00414	CcSEcCtD
Frovatriptan—Pharyngitis—Ezetimibe—atherosclerosis	0.00323	0.00412	CcSEcCtD
Frovatriptan—Depression—Pravastatin—atherosclerosis	0.00311	0.00398	CcSEcCtD
Frovatriptan—Stomatitis—Niacin—atherosclerosis	0.00309	0.00395	CcSEcCtD
Frovatriptan—Acute coronary syndrome—Pravastatin—atherosclerosis	0.00308	0.00393	CcSEcCtD
Frovatriptan—Flushing—Lovastatin—atherosclerosis	0.00308	0.00393	CcSEcCtD
Frovatriptan—Myocardial infarction—Pravastatin—atherosclerosis	0.00306	0.00391	CcSEcCtD
Frovatriptan—Flushing—Ezetimibe—atherosclerosis	0.00302	0.00385	CcSEcCtD
Frovatriptan—Chills—Lovastatin—atherosclerosis	0.00297	0.0038	CcSEcCtD
Frovatriptan—Sinusitis—Pravastatin—atherosclerosis	0.00293	0.00374	CcSEcCtD
Frovatriptan—Myalgia—Rosuvastatin—atherosclerosis	0.0029	0.0037	CcSEcCtD
Frovatriptan—Arthralgia—Rosuvastatin—atherosclerosis	0.0029	0.0037	CcSEcCtD
Frovatriptan—Flushing—Simvastatin—atherosclerosis	0.00288	0.00367	CcSEcCtD
Frovatriptan—Haemoglobin—Niacin—atherosclerosis	0.00286	0.00365	CcSEcCtD
Frovatriptan—Rhinitis—Niacin—atherosclerosis	0.00285	0.00364	CcSEcCtD
Frovatriptan—Mental disorder—Ezetimibe—atherosclerosis	0.00285	0.00364	CcSEcCtD
Frovatriptan—Haemorrhage—Niacin—atherosclerosis	0.00285	0.00363	CcSEcCtD
Frovatriptan—Flatulence—Lovastatin—atherosclerosis	0.00284	0.00363	CcSEcCtD
Frovatriptan—Hypoaesthesia—Niacin—atherosclerosis	0.00283	0.00362	CcSEcCtD
Frovatriptan—Malnutrition—Ezetimibe—atherosclerosis	0.00283	0.00361	CcSEcCtD
Frovatriptan—Dysgeusia—Lovastatin—atherosclerosis	0.00283	0.00361	CcSEcCtD
Frovatriptan—Rhinitis—Pravastatin—atherosclerosis	0.00281	0.00359	CcSEcCtD
Frovatriptan—Confusional state—Rosuvastatin—atherosclerosis	0.0028	0.00358	CcSEcCtD
Frovatriptan—Back pain—Lovastatin—atherosclerosis	0.00279	0.00356	CcSEcCtD
Frovatriptan—Hypoaesthesia—Pravastatin—atherosclerosis	0.00279	0.00356	CcSEcCtD
Frovatriptan—Flatulence—Ezetimibe—atherosclerosis	0.00279	0.00356	CcSEcCtD
Frovatriptan—Pharyngitis—Pravastatin—atherosclerosis	0.00278	0.00355	CcSEcCtD
Frovatriptan—Chills—Simvastatin—atherosclerosis	0.00278	0.00355	CcSEcCtD
Frovatriptan—Muscle spasms—Lovastatin—atherosclerosis	0.00277	0.00354	CcSEcCtD
Frovatriptan—Visual impairment—Niacin—atherosclerosis	0.00274	0.0035	CcSEcCtD
Frovatriptan—Back pain—Ezetimibe—atherosclerosis	0.00274	0.0035	CcSEcCtD
Frovatriptan—Muscle spasms—Ezetimibe—atherosclerosis	0.00272	0.00347	CcSEcCtD
Frovatriptan—Mental disorder—Simvastatin—atherosclerosis	0.00272	0.00347	CcSEcCtD
Frovatriptan—Tremor—Lovastatin—atherosclerosis	0.0027	0.00345	CcSEcCtD
Frovatriptan—Visual impairment—Pravastatin—atherosclerosis	0.0027	0.00345	CcSEcCtD
Frovatriptan—Ill-defined disorder—Lovastatin—atherosclerosis	0.00268	0.00342	CcSEcCtD
Frovatriptan—Flatulence—Simvastatin—atherosclerosis	0.00266	0.0034	CcSEcCtD
Frovatriptan—Tinnitus—Niacin—atherosclerosis	0.00265	0.00339	CcSEcCtD
Frovatriptan—Dysgeusia—Simvastatin—atherosclerosis	0.00264	0.00337	CcSEcCtD
Frovatriptan—Flushing—Niacin—atherosclerosis	0.00264	0.00337	CcSEcCtD
Frovatriptan—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00263	0.00335	CcSEcCtD
Frovatriptan—Tinnitus—Pravastatin—atherosclerosis	0.00261	0.00334	CcSEcCtD
Frovatriptan—Malaise—Lovastatin—atherosclerosis	0.0026	0.00332	CcSEcCtD
Frovatriptan—Flushing—Pravastatin—atherosclerosis	0.0026	0.00332	CcSEcCtD
Frovatriptan—Muscle spasms—Simvastatin—atherosclerosis	0.0026	0.00331	CcSEcCtD
Frovatriptan—Vertigo—Lovastatin—atherosclerosis	0.00259	0.00331	CcSEcCtD
Frovatriptan—Chills—Niacin—atherosclerosis	0.00255	0.00326	CcSEcCtD
Frovatriptan—Malaise—Ezetimibe—atherosclerosis	0.00255	0.00326	CcSEcCtD
Frovatriptan—Arrhythmia—Niacin—atherosclerosis	0.00254	0.00325	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00253	0.00323	CcSEcCtD
Frovatriptan—Tremor—Simvastatin—atherosclerosis	0.00253	0.00323	CcSEcCtD
Frovatriptan—Chills—Pravastatin—atherosclerosis	0.00252	0.00321	CcSEcCtD
Frovatriptan—Insomnia—Rosuvastatin—atherosclerosis	0.00251	0.00321	CcSEcCtD
Frovatriptan—Ill-defined disorder—Simvastatin—atherosclerosis	0.0025	0.0032	CcSEcCtD
Frovatriptan—Arrhythmia—Pravastatin—atherosclerosis	0.0025	0.0032	CcSEcCtD
Frovatriptan—Palpitations—Ezetimibe—atherosclerosis	0.0025	0.00319	CcSEcCtD
Frovatriptan—Paraesthesia—Rosuvastatin—atherosclerosis	0.0025	0.00319	CcSEcCtD
Frovatriptan—Malnutrition—Niacin—atherosclerosis	0.00248	0.00316	CcSEcCtD
Frovatriptan—Chest pain—Lovastatin—atherosclerosis	0.00246	0.00314	CcSEcCtD
Frovatriptan—Myalgia—Lovastatin—atherosclerosis	0.00246	0.00314	CcSEcCtD
Frovatriptan—Arthralgia—Lovastatin—atherosclerosis	0.00246	0.00314	CcSEcCtD
Frovatriptan—Anxiety—Lovastatin—atherosclerosis	0.00245	0.00313	CcSEcCtD
Frovatriptan—Dyspepsia—Rosuvastatin—atherosclerosis	0.00245	0.00312	CcSEcCtD
Frovatriptan—Flatulence—Niacin—atherosclerosis	0.00244	0.00312	CcSEcCtD
Frovatriptan—Malaise—Simvastatin—atherosclerosis	0.00243	0.00311	CcSEcCtD
Frovatriptan—Tension—Niacin—atherosclerosis	0.00243	0.0031	CcSEcCtD
Frovatriptan—Discomfort—Lovastatin—atherosclerosis	0.00243	0.0031	CcSEcCtD
Frovatriptan—Vertigo—Simvastatin—atherosclerosis	0.00243	0.0031	CcSEcCtD
Frovatriptan—Myalgia—Ezetimibe—atherosclerosis	0.00241	0.00308	CcSEcCtD
Frovatriptan—Chest pain—Ezetimibe—atherosclerosis	0.00241	0.00308	CcSEcCtD
Frovatriptan—Arthralgia—Ezetimibe—atherosclerosis	0.00241	0.00308	CcSEcCtD
Frovatriptan—Nervousness—Niacin—atherosclerosis	0.00241	0.00307	CcSEcCtD
Frovatriptan—Flatulence—Pravastatin—atherosclerosis	0.0024	0.00307	CcSEcCtD
Frovatriptan—Dry mouth—Lovastatin—atherosclerosis	0.0024	0.00307	CcSEcCtD
Frovatriptan—Tension—Pravastatin—atherosclerosis	0.00239	0.00306	CcSEcCtD
Frovatriptan—Dysgeusia—Pravastatin—atherosclerosis	0.00239	0.00305	CcSEcCtD
Frovatriptan—Muscle spasms—Niacin—atherosclerosis	0.00238	0.00304	CcSEcCtD
Frovatriptan—Discomfort—Ezetimibe—atherosclerosis	0.00238	0.00304	CcSEcCtD
Frovatriptan—Pain—Rosuvastatin—atherosclerosis	0.00238	0.00303	CcSEcCtD
Frovatriptan—Constipation—Rosuvastatin—atherosclerosis	0.00238	0.00303	CcSEcCtD
Frovatriptan—Confusional state—Lovastatin—atherosclerosis	0.00238	0.00303	CcSEcCtD
Frovatriptan—Nervousness—Pravastatin—atherosclerosis	0.00237	0.00303	CcSEcCtD
Frovatriptan—Dry mouth—Ezetimibe—atherosclerosis	0.00236	0.00301	CcSEcCtD
Frovatriptan—Anaphylactic shock—Lovastatin—atherosclerosis	0.00236	0.00301	CcSEcCtD
Frovatriptan—Muscle spasms—Pravastatin—atherosclerosis	0.00235	0.003	CcSEcCtD
Frovatriptan—Confusional state—Ezetimibe—atherosclerosis	0.00233	0.00297	CcSEcCtD
Frovatriptan—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00231	0.00295	CcSEcCtD
Frovatriptan—Chest pain—Simvastatin—atherosclerosis	0.0023	0.00293	CcSEcCtD
Frovatriptan—Arthralgia—Simvastatin—atherosclerosis	0.0023	0.00293	CcSEcCtD
Frovatriptan—Myalgia—Simvastatin—atherosclerosis	0.0023	0.00293	CcSEcCtD
Frovatriptan—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00229	0.00292	CcSEcCtD
Frovatriptan—Anxiety—Simvastatin—atherosclerosis	0.00229	0.00292	CcSEcCtD
Frovatriptan—Tremor—Pravastatin—atherosclerosis	0.00229	0.00292	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00227	0.0029	CcSEcCtD
Frovatriptan—Discomfort—Simvastatin—atherosclerosis	0.00227	0.0029	CcSEcCtD
Frovatriptan—Ill-defined disorder—Pravastatin—atherosclerosis	0.00226	0.00289	CcSEcCtD
Frovatriptan—Anorexia—Lovastatin—atherosclerosis	0.00225	0.00287	CcSEcCtD
Frovatriptan—Vertigo—Niacin—atherosclerosis	0.00223	0.00284	CcSEcCtD
Frovatriptan—Syncope—Niacin—atherosclerosis	0.00222	0.00284	CcSEcCtD
Frovatriptan—Confusional state—Simvastatin—atherosclerosis	0.00222	0.00284	CcSEcCtD
Frovatriptan—Anaphylactic shock—Simvastatin—atherosclerosis	0.0022	0.00281	CcSEcCtD
Frovatriptan—Malaise—Pravastatin—atherosclerosis	0.0022	0.00281	CcSEcCtD
Frovatriptan—Abdominal pain—Rosuvastatin—atherosclerosis	0.0022	0.0028	CcSEcCtD
Frovatriptan—Vertigo—Pravastatin—atherosclerosis	0.00219	0.0028	CcSEcCtD
Frovatriptan—Palpitations—Niacin—atherosclerosis	0.00219	0.0028	CcSEcCtD
Frovatriptan—Loss of consciousness—Niacin—atherosclerosis	0.00218	0.00278	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00215	0.00274	CcSEcCtD
Frovatriptan—Insomnia—Lovastatin—atherosclerosis	0.00213	0.00272	CcSEcCtD
Frovatriptan—Paraesthesia—Lovastatin—atherosclerosis	0.00212	0.0027	CcSEcCtD
Frovatriptan—Myalgia—Niacin—atherosclerosis	0.00211	0.00269	CcSEcCtD
Frovatriptan—Arthralgia—Niacin—atherosclerosis	0.00211	0.00269	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.0021	0.00269	CcSEcCtD
Frovatriptan—Anorexia—Simvastatin—atherosclerosis	0.0021	0.00268	CcSEcCtD
Frovatriptan—Dyspnoea—Lovastatin—atherosclerosis	0.0021	0.00268	CcSEcCtD
Frovatriptan—Insomnia—Ezetimibe—atherosclerosis	0.00209	0.00267	CcSEcCtD
Frovatriptan—Myalgia—Pravastatin—atherosclerosis	0.00208	0.00265	CcSEcCtD
Frovatriptan—Chest pain—Pravastatin—atherosclerosis	0.00208	0.00265	CcSEcCtD
Frovatriptan—Arthralgia—Pravastatin—atherosclerosis	0.00208	0.00265	CcSEcCtD
Frovatriptan—Paraesthesia—Ezetimibe—atherosclerosis	0.00207	0.00265	CcSEcCtD
Frovatriptan—Dyspepsia—Lovastatin—atherosclerosis	0.00207	0.00265	CcSEcCtD
Frovatriptan—Anxiety—Pravastatin—atherosclerosis	0.00207	0.00264	CcSEcCtD
Frovatriptan—Dry mouth—Niacin—atherosclerosis	0.00206	0.00263	CcSEcCtD
Frovatriptan—Dyspnoea—Ezetimibe—atherosclerosis	0.00206	0.00263	CcSEcCtD
Frovatriptan—Discomfort—Pravastatin—atherosclerosis	0.00205	0.00262	CcSEcCtD
Frovatriptan—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00205	0.00261	CcSEcCtD
Frovatriptan—Decreased appetite—Lovastatin—atherosclerosis	0.00205	0.00261	CcSEcCtD
Frovatriptan—Dyspepsia—Ezetimibe—atherosclerosis	0.00203	0.0026	CcSEcCtD
Frovatriptan—Fatigue—Lovastatin—atherosclerosis	0.00203	0.00259	CcSEcCtD
Frovatriptan—Anaphylactic shock—Niacin—atherosclerosis	0.00202	0.00258	CcSEcCtD
Frovatriptan—Constipation—Lovastatin—atherosclerosis	0.00201	0.00257	CcSEcCtD
Frovatriptan—Pain—Lovastatin—atherosclerosis	0.00201	0.00257	CcSEcCtD
Frovatriptan—Confusional state—Pravastatin—atherosclerosis	0.00201	0.00256	CcSEcCtD
Frovatriptan—Decreased appetite—Ezetimibe—atherosclerosis	0.00201	0.00256	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00201	0.00256	CcSEcCtD
Frovatriptan—Asthenia—Rosuvastatin—atherosclerosis	0.00199	0.00255	CcSEcCtD
Frovatriptan—Insomnia—Simvastatin—atherosclerosis	0.00199	0.00254	CcSEcCtD
Frovatriptan—Anaphylactic shock—Pravastatin—atherosclerosis	0.00199	0.00254	CcSEcCtD
Frovatriptan—Fatigue—Ezetimibe—atherosclerosis	0.00199	0.00254	CcSEcCtD
Frovatriptan—Shock—Niacin—atherosclerosis	0.00199	0.00254	CcSEcCtD
Frovatriptan—Paraesthesia—Simvastatin—atherosclerosis	0.00198	0.00253	CcSEcCtD
Frovatriptan—Pain—Ezetimibe—atherosclerosis	0.00198	0.00252	CcSEcCtD
Frovatriptan—Constipation—Ezetimibe—atherosclerosis	0.00198	0.00252	CcSEcCtD
Frovatriptan—Tachycardia—Niacin—atherosclerosis	0.00197	0.00252	CcSEcCtD
Frovatriptan—Pruritus—Rosuvastatin—atherosclerosis	0.00197	0.00251	CcSEcCtD
Frovatriptan—Dyspnoea—Simvastatin—atherosclerosis	0.00196	0.00251	CcSEcCtD
Frovatriptan—Hyperhidrosis—Niacin—atherosclerosis	0.00196	0.0025	CcSEcCtD
Frovatriptan—Feeling abnormal—Lovastatin—atherosclerosis	0.00194	0.00248	CcSEcCtD
Frovatriptan—Dyspepsia—Simvastatin—atherosclerosis	0.00194	0.00248	CcSEcCtD
Frovatriptan—Anorexia—Niacin—atherosclerosis	0.00193	0.00246	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00193	0.00246	CcSEcCtD
Frovatriptan—Hyperhidrosis—Pravastatin—atherosclerosis	0.00193	0.00246	CcSEcCtD
Frovatriptan—Decreased appetite—Simvastatin—atherosclerosis	0.00192	0.00244	CcSEcCtD
Frovatriptan—Feeling abnormal—Ezetimibe—atherosclerosis	0.0019	0.00243	CcSEcCtD
Frovatriptan—Diarrhoea—Rosuvastatin—atherosclerosis	0.0019	0.00243	CcSEcCtD
Frovatriptan—Fatigue—Simvastatin—atherosclerosis	0.0019	0.00242	CcSEcCtD
Frovatriptan—Anorexia—Pravastatin—atherosclerosis	0.0019	0.00242	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00189	0.00241	CcSEcCtD
Frovatriptan—Pain—Simvastatin—atherosclerosis	0.00188	0.0024	CcSEcCtD
Frovatriptan—Constipation—Simvastatin—atherosclerosis	0.00188	0.0024	CcSEcCtD
Frovatriptan—Body temperature increased—Lovastatin—atherosclerosis	0.00186	0.00238	CcSEcCtD
Frovatriptan—Abdominal pain—Lovastatin—atherosclerosis	0.00186	0.00238	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00184	0.00235	CcSEcCtD
Frovatriptan—Dizziness—Rosuvastatin—atherosclerosis	0.00184	0.00235	CcSEcCtD
Frovatriptan—Insomnia—Niacin—atherosclerosis	0.00183	0.00234	CcSEcCtD
Frovatriptan—Abdominal pain—Ezetimibe—atherosclerosis	0.00183	0.00233	CcSEcCtD
Frovatriptan—Body temperature increased—Ezetimibe—atherosclerosis	0.00183	0.00233	CcSEcCtD
Frovatriptan—Paraesthesia—Niacin—atherosclerosis	0.00182	0.00232	CcSEcCtD
Frovatriptan—Feeling abnormal—Simvastatin—atherosclerosis	0.00182	0.00232	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00181	0.00232	CcSEcCtD
Frovatriptan—Dyspnoea—Niacin—atherosclerosis	0.0018	0.0023	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Simvastatin—atherosclerosis	0.0018	0.0023	CcSEcCtD
Frovatriptan—Insomnia—Pravastatin—atherosclerosis	0.0018	0.0023	CcSEcCtD
Frovatriptan—Somnolence—Niacin—atherosclerosis	0.0018	0.0023	CcSEcCtD
Frovatriptan—Paraesthesia—Pravastatin—atherosclerosis	0.00179	0.00228	CcSEcCtD
Frovatriptan—Dyspepsia—Niacin—atherosclerosis	0.00178	0.00227	CcSEcCtD
Frovatriptan—Dyspnoea—Pravastatin—atherosclerosis	0.00178	0.00227	CcSEcCtD
Frovatriptan—Decreased appetite—Niacin—atherosclerosis	0.00176	0.00224	CcSEcCtD
Frovatriptan—Dyspepsia—Pravastatin—atherosclerosis	0.00175	0.00224	CcSEcCtD
Frovatriptan—Abdominal pain—Simvastatin—atherosclerosis	0.00174	0.00222	CcSEcCtD
Frovatriptan—Body temperature increased—Simvastatin—atherosclerosis	0.00174	0.00222	CcSEcCtD
Frovatriptan—Headache—Rosuvastatin—atherosclerosis	0.00174	0.00222	CcSEcCtD
Frovatriptan—Hypersensitivity—Lovastatin—atherosclerosis	0.00174	0.00222	CcSEcCtD
Frovatriptan—Decreased appetite—Pravastatin—atherosclerosis	0.00173	0.00221	CcSEcCtD
Frovatriptan—Pain—Niacin—atherosclerosis	0.00173	0.00221	CcSEcCtD
Frovatriptan—Fatigue—Pravastatin—atherosclerosis	0.00172	0.00219	CcSEcCtD
Frovatriptan—Pain—Pravastatin—atherosclerosis	0.0017	0.00217	CcSEcCtD
Frovatriptan—Constipation—Pravastatin—atherosclerosis	0.0017	0.00217	CcSEcCtD
Frovatriptan—Hypersensitivity—Ezetimibe—atherosclerosis	0.0017	0.00217	CcSEcCtD
Frovatriptan—Asthenia—Lovastatin—atherosclerosis	0.00169	0.00216	CcSEcCtD
Frovatriptan—Pruritus—Lovastatin—atherosclerosis	0.00167	0.00213	CcSEcCtD
Frovatriptan—Asthenia—Ezetimibe—atherosclerosis	0.00166	0.00212	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Niacin—atherosclerosis	0.00165	0.00211	CcSEcCtD
Frovatriptan—Nausea—Rosuvastatin—atherosclerosis	0.00165	0.00211	CcSEcCtD
Frovatriptan—Feeling abnormal—Pravastatin—atherosclerosis	0.00164	0.0021	CcSEcCtD
Frovatriptan—Pruritus—Ezetimibe—atherosclerosis	0.00163	0.00209	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00163	0.00208	CcSEcCtD
Frovatriptan—Hypersensitivity—Simvastatin—atherosclerosis	0.00162	0.00207	CcSEcCtD
Frovatriptan—Diarrhoea—Lovastatin—atherosclerosis	0.00161	0.00206	CcSEcCtD
Frovatriptan—Body temperature increased—Niacin—atherosclerosis	0.0016	0.00204	CcSEcCtD
Frovatriptan—Abdominal pain—Niacin—atherosclerosis	0.0016	0.00204	CcSEcCtD
Frovatriptan—Asthenia—Simvastatin—atherosclerosis	0.00158	0.00202	CcSEcCtD
Frovatriptan—Diarrhoea—Ezetimibe—atherosclerosis	0.00158	0.00202	CcSEcCtD
Frovatriptan—Body temperature increased—Pravastatin—atherosclerosis	0.00157	0.00201	CcSEcCtD
Frovatriptan—Abdominal pain—Pravastatin—atherosclerosis	0.00157	0.00201	CcSEcCtD
Frovatriptan—Pruritus—Simvastatin—atherosclerosis	0.00156	0.00199	CcSEcCtD
Frovatriptan—Dizziness—Lovastatin—atherosclerosis	0.00156	0.00199	CcSEcCtD
Frovatriptan—Dizziness—Ezetimibe—atherosclerosis	0.00153	0.00195	CcSEcCtD
Frovatriptan—Diarrhoea—Simvastatin—atherosclerosis	0.00151	0.00192	CcSEcCtD
Frovatriptan—Vomiting—Lovastatin—atherosclerosis	0.0015	0.00191	CcSEcCtD
Frovatriptan—Hypersensitivity—Niacin—atherosclerosis	0.00149	0.0019	CcSEcCtD
Frovatriptan—Headache—Lovastatin—atherosclerosis	0.00148	0.00188	CcSEcCtD
Frovatriptan—Vomiting—Ezetimibe—atherosclerosis	0.00147	0.00188	CcSEcCtD
Frovatriptan—Hypersensitivity—Pravastatin—atherosclerosis	0.00147	0.00187	CcSEcCtD
Frovatriptan—Dizziness—Simvastatin—atherosclerosis	0.00146	0.00186	CcSEcCtD
Frovatriptan—Asthenia—Niacin—atherosclerosis	0.00145	0.00185	CcSEcCtD
Frovatriptan—Headache—Ezetimibe—atherosclerosis	0.00145	0.00185	CcSEcCtD
Frovatriptan—Pruritus—Niacin—atherosclerosis	0.00143	0.00183	CcSEcCtD
Frovatriptan—Asthenia—Pravastatin—atherosclerosis	0.00143	0.00182	CcSEcCtD
Frovatriptan—Pruritus—Pravastatin—atherosclerosis	0.00141	0.0018	CcSEcCtD
Frovatriptan—Vomiting—Simvastatin—atherosclerosis	0.0014	0.00179	CcSEcCtD
Frovatriptan—Nausea—Lovastatin—atherosclerosis	0.0014	0.00179	CcSEcCtD
Frovatriptan—Diarrhoea—Niacin—atherosclerosis	0.00138	0.00177	CcSEcCtD
Frovatriptan—Headache—Simvastatin—atherosclerosis	0.00138	0.00176	CcSEcCtD
Frovatriptan—Nausea—Ezetimibe—atherosclerosis	0.00137	0.00175	CcSEcCtD
Frovatriptan—Diarrhoea—Pravastatin—atherosclerosis	0.00136	0.00174	CcSEcCtD
Frovatriptan—HTR1B—artery—atherosclerosis	0.00136	0.201	CbGeAlD
Frovatriptan—Dizziness—Niacin—atherosclerosis	0.00134	0.00171	CcSEcCtD
Frovatriptan—Dizziness—Pravastatin—atherosclerosis	0.00132	0.00168	CcSEcCtD
Frovatriptan—HTR1D—artery—atherosclerosis	0.00131	0.194	CbGeAlD
Frovatriptan—Nausea—Simvastatin—atherosclerosis	0.00131	0.00167	CcSEcCtD
Frovatriptan—Vomiting—Niacin—atherosclerosis	0.00129	0.00164	CcSEcCtD
Frovatriptan—Headache—Niacin—atherosclerosis	0.00127	0.00162	CcSEcCtD
Frovatriptan—Vomiting—Pravastatin—atherosclerosis	0.00127	0.00162	CcSEcCtD
Frovatriptan—Headache—Pravastatin—atherosclerosis	0.00125	0.00159	CcSEcCtD
Frovatriptan—Nausea—Niacin—atherosclerosis	0.0012	0.00153	CcSEcCtD
Frovatriptan—Nausea—Pravastatin—atherosclerosis	0.00118	0.00151	CcSEcCtD
Frovatriptan—HTR1B—blood vessel—atherosclerosis	0.00106	0.156	CbGeAlD
Frovatriptan—HTR1D—blood vessel—atherosclerosis	0.00102	0.151	CbGeAlD
Frovatriptan—HTR1D—connective tissue—atherosclerosis	0.000525	0.0776	CbGeAlD
Frovatriptan—HTR1B—cardiovascular system—atherosclerosis	0.000472	0.0697	CbGeAlD
Frovatriptan—HTR1D—cardiovascular system—atherosclerosis	0.000457	0.0675	CbGeAlD
Frovatriptan—HTR1A—cardiovascular system—atherosclerosis	0.000381	0.0563	CbGeAlD
Frovatriptan—CYP1A2—liver—atherosclerosis	0.00018	0.0265	CbGeAlD
Frovatriptan—HTR1A—Signaling Pathways—UTS2—atherosclerosis	0.000142	0.000678	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PLTP—atherosclerosis	0.000142	0.000678	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—AGTR1—atherosclerosis	0.000142	0.000677	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—NCF1—atherosclerosis	0.00014	0.000667	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—NCF1—atherosclerosis	0.000137	0.000654	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CX3CR1—atherosclerosis	0.000136	0.00065	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CASR—atherosclerosis	0.000136	0.00065	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—F2—atherosclerosis	0.000136	0.00065	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—AGT—atherosclerosis	0.000134	0.000638	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CX3CL1—atherosclerosis	0.000134	0.000638	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—F2—atherosclerosis	0.000133	0.000636	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—EDN1—atherosclerosis	0.000133	0.000632	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCR2—atherosclerosis	0.000132	0.00063	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—EDNRA—atherosclerosis	0.000132	0.00063	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—atherosclerosis	0.000132	0.000628	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CYBA—atherosclerosis	0.000132	0.000628	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—CCL5—atherosclerosis	0.000132	0.000627	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—AGT—atherosclerosis	0.000131	0.000625	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—APOC3—atherosclerosis	0.000131	0.000624	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—PIK3CG—atherosclerosis	0.00013	0.000622	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—LDLR—atherosclerosis	0.00013	0.00062	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCR2—atherosclerosis	0.00013	0.000617	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—EDNRA—atherosclerosis	0.00013	0.000617	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CYBA—atherosclerosis	0.000129	0.000614	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—GHRL—atherosclerosis	0.000129	0.000614	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PLAT—atherosclerosis	0.000129	0.000614	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PARP1—atherosclerosis	0.000129	0.000614	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000128	0.000609	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CETP—atherosclerosis	0.000127	0.000606	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CNR2—atherosclerosis	0.000127	0.000605	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—CXCL8—atherosclerosis	0.000127	0.000604	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—MMP3—atherosclerosis	0.000127	0.000603	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PLAT—atherosclerosis	0.000126	0.000601	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—GHRL—atherosclerosis	0.000126	0.000601	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PARP1—atherosclerosis	0.000126	0.000601	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—PRKCG—atherosclerosis	0.000125	0.000596	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—F2—atherosclerosis	0.000124	0.00059	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—LTA4H—atherosclerosis	0.000123	0.000588	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ABCG8—atherosclerosis	0.000123	0.000588	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—atherosclerosis	0.000122	0.00058	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—F2—atherosclerosis	0.000121	0.000578	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—EDN1—atherosclerosis	0.00012	0.000574	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CCL5—atherosclerosis	0.000119	0.000569	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—PIK3CG—atherosclerosis	0.000118	0.000565	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—PIK3CG—atherosclerosis	0.000116	0.000553	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—HMGCR—atherosclerosis	0.000115	0.000548	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—PRKCG—atherosclerosis	0.000114	0.000541	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—KNG1—atherosclerosis	0.000113	0.000539	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—VWF—atherosclerosis	0.000113	0.000539	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—AGTR1—atherosclerosis	0.000112	0.000536	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—APOC3—atherosclerosis	0.000112	0.000536	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—LDLR—atherosclerosis	0.000112	0.000532	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—KNG1—atherosclerosis	0.000111	0.000528	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CCL2—atherosclerosis	0.00011	0.000526	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—AGTR1—atherosclerosis	0.00011	0.000525	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—AGT—atherosclerosis	0.00011	0.000524	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PLG—atherosclerosis	0.00011	0.000522	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCL3—atherosclerosis	0.000109	0.00052	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CCL2—atherosclerosis	0.000108	0.000515	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PLG—atherosclerosis	0.000107	0.000511	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—NCF1—atherosclerosis	0.000104	0.000498	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—SOCS3—atherosclerosis	0.000104	0.000495	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	0.000102	0.000488	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—F2—atherosclerosis	0.000102	0.000485	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—SOCS3—atherosclerosis	0.000102	0.000484	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MMP3—atherosclerosis	0.0001	0.000478	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—AGT—atherosclerosis	9.99e-05	0.000476	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—IGF2—atherosclerosis	9.98e-05	0.000476	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—EDNRA—atherosclerosis	9.87e-05	0.00047	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCR2—atherosclerosis	9.87e-05	0.00047	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CYBA—atherosclerosis	9.82e-05	0.000468	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MMP3—atherosclerosis	9.81e-05	0.000468	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—IGF2—atherosclerosis	9.77e-05	0.000466	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ABCG1—atherosclerosis	9.74e-05	0.000464	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—PIK3CG—atherosclerosis	9.73e-05	0.000464	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—APOB—atherosclerosis	9.69e-05	0.000462	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PLAT—atherosclerosis	9.61e-05	0.000458	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PARP1—atherosclerosis	9.61e-05	0.000458	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—GHRL—atherosclerosis	9.61e-05	0.000458	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—CXCL8—atherosclerosis	9.61e-05	0.000458	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—EDN1—atherosclerosis	9.53e-05	0.000454	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—APOB—atherosclerosis	9.49e-05	0.000452	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCL5—atherosclerosis	9.46e-05	0.000451	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—CXCL8—atherosclerosis	9.41e-05	0.000448	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—EDN1—atherosclerosis	9.34e-05	0.000445	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCL5—atherosclerosis	9.26e-05	0.000441	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—LPL—atherosclerosis	9.25e-05	0.000441	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—F2—atherosclerosis	9.23e-05	0.00044	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—FABP4—atherosclerosis	9.16e-05	0.000437	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—LCAT—atherosclerosis	9.16e-05	0.000437	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—LPL—atherosclerosis	9.06e-05	0.000432	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PRKCG—atherosclerosis	8.99e-05	0.000429	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—APOA4—atherosclerosis	8.99e-05	0.000429	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—PIK3CG—atherosclerosis	8.84e-05	0.000421	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP7A1—atherosclerosis	8.83e-05	0.000421	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PRKCG—atherosclerosis	8.81e-05	0.00042	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—SPP1—atherosclerosis	8.76e-05	0.000418	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CXCL8—atherosclerosis	8.72e-05	0.000416	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—SPP1—atherosclerosis	8.58e-05	0.000409	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CXCL8—atherosclerosis	8.54e-05	0.000407	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—KNG1—atherosclerosis	8.44e-05	0.000402	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	8.42e-05	0.000401	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—AGTR1—atherosclerosis	8.39e-05	0.0004	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CCL2—atherosclerosis	8.23e-05	0.000392	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PLG—atherosclerosis	8.17e-05	0.00039	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP27A1—atherosclerosis	8.17e-05	0.000389	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PDGFB—atherosclerosis	8.11e-05	0.000386	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	8.04e-05	0.000383	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PDGFB—atherosclerosis	7.94e-05	0.000378	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—AGT—atherosclerosis	7.91e-05	0.000377	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	7.84e-05	0.000374	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—LEP—atherosclerosis	7.75e-05	0.00037	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—APOE—atherosclerosis	7.75e-05	0.00037	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—AGT—atherosclerosis	7.75e-05	0.000369	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—SOCS3—atherosclerosis	7.74e-05	0.000369	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ALOX5AP—atherosclerosis	7.74e-05	0.000369	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ALOX15—atherosclerosis	7.74e-05	0.000369	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PLA2G2A—atherosclerosis	7.74e-05	0.000369	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—APOA2—atherosclerosis	7.74e-05	0.000369	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CAV1—atherosclerosis	7.68e-05	0.000366	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—APOA1—atherosclerosis	7.66e-05	0.000365	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ABCG5—atherosclerosis	7.65e-05	0.000364	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	7.64e-05	0.000364	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—APOE—atherosclerosis	7.59e-05	0.000362	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—LEP—atherosclerosis	7.59e-05	0.000362	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CAV1—atherosclerosis	7.52e-05	0.000359	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—APOA1—atherosclerosis	7.51e-05	0.000358	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MMP3—atherosclerosis	7.48e-05	0.000356	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IGF2—atherosclerosis	7.44e-05	0.000355	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—ESR1—atherosclerosis	7.4e-05	0.000353	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—LPA—atherosclerosis	7.39e-05	0.000352	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—F2—atherosclerosis	7.31e-05	0.000348	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—ESR1—atherosclerosis	7.25e-05	0.000345	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—APOB—atherosclerosis	7.23e-05	0.000344	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—CXCL8—atherosclerosis	7.16e-05	0.000341	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—F2—atherosclerosis	7.16e-05	0.000341	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—BGN—atherosclerosis	7.15e-05	0.000341	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—EDN1—atherosclerosis	7.11e-05	0.000339	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	7.1e-05	0.000338	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—APOA5—atherosclerosis	7.08e-05	0.000337	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCL5—atherosclerosis	7.06e-05	0.000336	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PIK3CG—atherosclerosis	7e-05	0.000334	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—LPL—atherosclerosis	6.9e-05	0.000329	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	6.88e-05	0.000328	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PIK3CG—atherosclerosis	6.85e-05	0.000327	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	6.82e-05	0.000325	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	6.74e-05	0.000321	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PRKCG—atherosclerosis	6.71e-05	0.00032	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—MAPK3—atherosclerosis	6.7e-05	0.000319	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	6.68e-05	0.000318	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	6.66e-05	0.000317	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—INS—atherosclerosis	6.62e-05	0.000316	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ALOX5—atherosclerosis	6.58e-05	0.000314	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—MAPK3—atherosclerosis	6.56e-05	0.000313	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—SPP1—atherosclerosis	6.54e-05	0.000311	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCL2—atherosclerosis	6.52e-05	0.000311	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CXCL8—atherosclerosis	6.51e-05	0.00031	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—INS—atherosclerosis	6.49e-05	0.000309	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—IGF1—atherosclerosis	6.41e-05	0.000305	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCL2—atherosclerosis	6.38e-05	0.000304	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—IGF1—atherosclerosis	6.27e-05	0.000299	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—SERPINE1—atherosclerosis	6.08e-05	0.00029	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	6.08e-05	0.00029	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PDGFB—atherosclerosis	6.05e-05	0.000288	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—SERPINE1—atherosclerosis	5.96e-05	0.000284	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NAMPT—atherosclerosis	5.9e-05	0.000281	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—AGT—atherosclerosis	5.9e-05	0.000281	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	5.87e-05	0.00028	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—LIPC—atherosclerosis	5.87e-05	0.00028	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—APOC3—atherosclerosis	5.83e-05	0.000278	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—NOS3—atherosclerosis	5.81e-05	0.000277	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—LDLR—atherosclerosis	5.8e-05	0.000276	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—APOE—atherosclerosis	5.78e-05	0.000276	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—LEP—atherosclerosis	5.78e-05	0.000276	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CAV1—atherosclerosis	5.73e-05	0.000273	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—APOA1—atherosclerosis	5.72e-05	0.000272	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—NOS3—atherosclerosis	5.69e-05	0.000271	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CETP—atherosclerosis	5.66e-05	0.00027	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ESR1—atherosclerosis	5.52e-05	0.000263	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—F2—atherosclerosis	5.45e-05	0.00026	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—SCARB1—atherosclerosis	5.42e-05	0.000258	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	5.28e-05	0.000252	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PIK3CG—atherosclerosis	5.22e-05	0.000249	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CXCL8—atherosclerosis	5.15e-05	0.000246	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—HMGCR—atherosclerosis	5.12e-05	0.000244	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CXCL8—atherosclerosis	5.05e-05	0.00024	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	5e-05	0.000238	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—AKT1—atherosclerosis	4.98e-05	0.000237	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—INS—atherosclerosis	4.94e-05	0.000235	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—IL6—atherosclerosis	4.9e-05	0.000234	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—AKT1—atherosclerosis	4.87e-05	0.000232	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCL2—atherosclerosis	4.86e-05	0.000232	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—IL6—atherosclerosis	4.8e-05	0.000229	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IGF1—atherosclerosis	4.78e-05	0.000228	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MMP9—atherosclerosis	4.66e-05	0.000222	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	4.62e-05	0.00022	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—NFKB1—atherosclerosis	4.61e-05	0.00022	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MMP9—atherosclerosis	4.56e-05	0.000217	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ABCA1—atherosclerosis	4.56e-05	0.000217	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	4.54e-05	0.000216	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MAPK8—atherosclerosis	4.53e-05	0.000216	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—AKT1—atherosclerosis	4.52e-05	0.000215	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—NFKB1—atherosclerosis	4.52e-05	0.000215	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MAPK8—atherosclerosis	4.44e-05	0.000212	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—AKT1—atherosclerosis	4.43e-05	0.000211	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—NOS3—atherosclerosis	4.33e-05	0.000207	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	4.18e-05	0.000199	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—STAT3—atherosclerosis	4.14e-05	0.000197	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	4.1e-05	0.000195	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—STAT3—atherosclerosis	4.06e-05	0.000193	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	3.96e-05	0.000189	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—HMOX1—atherosclerosis	3.91e-05	0.000187	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	3.88e-05	0.000185	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	3.84e-05	0.000183	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	3.84e-05	0.000183	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	3.76e-05	0.000179	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—APOB—atherosclerosis	3.75e-05	0.000179	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	3.71e-05	0.000177	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—IL6—atherosclerosis	3.65e-05	0.000174	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GSTM1—atherosclerosis	3.65e-05	0.000174	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—LPL—atherosclerosis	3.58e-05	0.000171	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GPX1—atherosclerosis	3.49e-05	0.000166	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MMP9—atherosclerosis	3.48e-05	0.000166	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	3.44e-05	0.000164	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CD36—atherosclerosis	3.4e-05	0.000162	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	3.38e-05	0.000161	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	3.37e-05	0.000161	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—MTHFR—atherosclerosis	3.22e-05	0.000154	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PPARA—atherosclerosis	3.16e-05	0.000151	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	3.12e-05	0.000149	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—STAT3—atherosclerosis	3.09e-05	0.000147	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—AGT—atherosclerosis	3.06e-05	0.000146	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—APOE—atherosclerosis	3e-05	0.000143	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CAV1—atherosclerosis	2.97e-05	0.000142	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—APOA1—atherosclerosis	2.97e-05	0.000141	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	2.95e-05	0.000141	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—IL6—atherosclerosis	2.89e-05	0.000138	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	2.87e-05	0.000137	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—IL6—atherosclerosis	2.83e-05	0.000135	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PIK3CG—atherosclerosis	2.71e-05	0.000129	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—AKT1—atherosclerosis	2.67e-05	0.000127	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—AKT1—atherosclerosis	2.61e-05	0.000125	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PPARG—atherosclerosis	2.61e-05	0.000125	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—INS—atherosclerosis	2.56e-05	0.000122	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ALB—atherosclerosis	2.35e-05	0.000112	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—NOS3—atherosclerosis	2.25e-05	0.000107	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IL6—atherosclerosis	2.16e-05	0.000103	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—PTGS2—atherosclerosis	2.06e-05	9.8e-05	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.99e-05	9.49e-05	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—AKT1—atherosclerosis	1.03e-05	4.93e-05	CbGpPWpGaD
